{"classes":[{"categories":[{"measurements":[{"comment":"Data could not be calculated due to insufficient number of events.","groupId":"OG000","lowerLimit":"4.402","upperLimit":"NA","value":"10.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"DOCR was defined from the first response (CR or CRc) to the time of relapse or death from any cause, whichever came first. CR was defined as normalization of blast percentage (≤ 5%); normalization of neutrophil count (≥ 1000/μL) and platelet count (≥ 100,000/μL); absence of leukemic blasts; 100% clearance of all skin lesions from baseline; no new lesions in participants without lesions at baseline; nodal masses regression to normal size on CT; and spleen and liver not palpable and nodules disappeared. CRc was defined as normalization of blast percentage (≤ 5%); normalization of neutrophil count (≥ 1000/μL) and platelet count (≥ 100,000/μL); absence of leukemic blasts; marked clearance of all skin lesions from baseline, residual hyperpigmentation or abnormality with BPDCN identified on biopsy (or no biopsy performed); nodal masses regression to normal size on CT; and spleen and liver not palpable and nodules disappeared. Median and 95% CI were calculated by Kaplan-Meier estimation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMGN632 via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Frontline De Novo BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg"}],"paramType":"MEDIAN","populationDescription":"mITT Population included all participants who were eligible based on the screening criteria and who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = Frontline de novo BPDCN participants with CR or CRc. Per protocol, this endpoint evaluated only Frontline de novo BPDCN participants with CR or CRc, all of whom were in arm Schedule A: IMGN632 0.045 mg/kg.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Duration of CCR (DOCR) As Assessed by Investigator in Frontline De Novo BPDCN Participants With CR or CRc","type":"SECONDARY","unitOfMeasure":"months"}